SND 562
Alternative Names: SND-562Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Floratek Pharma
- Class Antineoplastics; Polyphenols; Small molecules
- Mechanism of Action CKAP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lymphoma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 19 Dec 2024 Preclinical trials in Ovarian cancer in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)
- 19 Dec 2024 Preclinical trials in Pancreatic cancer in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)
- 22 Mar 2024 Preclinical trials in Lymphoma in Switzerland (unspecified route) before December 2024